Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC (REGSIN)

Regorafenib Combined With Sintilimab Versus Regorafenib Alone as the Second-line Treatment for Unresectable Hepatocellular Carcinoma

This study is conducted to evaluate the efficacy and safety of regorafenib plus sintilimab compared with regorafenib alone as the second-line treatment for patients with unresectable hepatocellullar carcinoma (HCC).

Study Overview

• Status: Active, not recruiting
• Conditions: Hepatocellular Carcinoma Non-resectable
• Intervention / Treatment: Drug: Regorafenib + sintilimab; Drug: Regorafenib

Detailed Description

This is an open-label, multicenter, randomized controlled trial to evaluate the efficacy and safety of regorafenib plus sintilimab compared with regorafenib alone as the second-line treatment for unresectable HCC.

180 patients with unresectable HCC who progress after sorafenib or lenvatinib treatment or are intolerant to these drugs will be enrolled in the study. The Patients will be treated with regorafenib plus sintilimab or regorafenib alone using an 1:1 randomization scheme.

Regorafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. The administration of regorafenib will be delayed in cases of severe toxicities. And after recovery, regorafenib will be reintroduced at a reduced dose according to the dose delay and reduction guidelines. Treatment of sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. In the arm of regorafenib plus sintilimab, patients will be allowed to have regorafenib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.

• Study Type: Interventional
• Enrollment (Actual): 166
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510260
      • The second Affiliated Hospital of Guangzhou Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with unresectable HCC confirmed by histology/cytology or clinically.
• Failure to prior sorafenib or lenvatinib treatment, or intolerance to sorafenib or lenvatinib.
• For patients who cannot tolerant to sorafenib or lenvatinib, the AEs must resolve to ≤ grade 1 (NCI-CTCAE v5.0) before randomization.
• Child-Pugh class A.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment.
• At least one measurable lesion.
• Adequate organ and hematologic function.
• Life expectancy of at least 3 months.
• For women of childbearing potential and for men: agreement to remain abstinent.

Exclusion Criteria:

• Diagnosis of fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
• Diffuse HCC.
• Portal vein tumor thrombus (PVTT) involves the main trunk and contralateral branch or upper mesenteric vein.
• Inferior vena cava tumor thrombus.
• Metastatic disease that involves major airways or blood vessels.
• Symptomatic, untreated or progressing central nervous system metastasis.
• History of hepatic encephalopathy
• History of organ and stem cell transplantation
• Uncontrolled ascites, hydrothorax or pericardial effusion
• Patients who receive systemic therapy except for sorafenib and lenvatinib within 4 weeks before randomization, including other molecular targeted drugs, chemotherapy (including hepatic arterial infusion chemotherapy), immunotherapy, and herbal therapy or traditional Chinese medicine with anti-cancer activity.
• Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment.
• Untreated or incompletely treated esophageal and/or gastric varices with high-risk for bleeding.
• History of venous thromboembolism, but implantable i.v. ports, catheter-derived thrombosis, superficial venous thrombosis, or thrombosis effectively treated by regular anticoagulant therapy are excluded.
• Use of anticoagulants which need monitoring of international normalized ratio.
• Patients unable to swallow oral medications; Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that may affect the absorption of regorafenib.
• Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture underwent major surgery (craniotomy, thoracotomy or open surgery) within 4 weeks; non-recovery from side effects of these procedure.
• Active tuberculosis.
• History of malignancy other than HCC within 5 years prior to screening. Patients with skin basal cell carcinoma, skin squamous cell carcinoma, or carcinoma in situ (e.g., breast carcinoma and cervical carcinoma in situ) who have received potentially curative treatment is allowed.
• Hepatitis B is allowed if no active replication is present. Hepatitis C is allowed if no antiviral treatment is required.
• Co-infection of hepatitis B virus (HBV) and hepatitis C virus (HCV) or HBV and hepatitis D virus (HDV).
• Active infection requiring systemic treatment. Hepatitis B without active replication is allowed. Hepatitis C not requiring antiviral treatment is allowed.
• Use of antibiotics within 2 weeks prior to injection of sintilimab.
• Use of immunosuppressive drugs in the past 4 weeks, excluding the routes of topical glucocorticoids or physiological doses of systemic glucocorticoids (ie no more than 10 mg/day of prednisone or equivalent). Temporary use of glucocorticoids for dyspnea symptoms such as asthma and chronic obstructive pulmonary disease is allowed.
• History of idiopathic pulmonary fibrosis, interstitial pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis.
• Autoimmune disease or immune deficiency.
• Inadequately controlled hypertension; history of hypertensive crisis or hypertensive encephalopathy.
• Female patients who are pregnancy or breastfeeding.
• Other acute or chronic diseases, mental illness, or abnormal laboratory test results that may lead to the following outcomes: increase the risk of participating in study or study drug administration, or interfere with the interpretation of the study results and considered by investigator as "NOT" eligible to participate in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Regorafenib + sintilimab; Regorafenib combined with sintilimab.	Drug: Regorafenib + sintilimab; Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off). Sintilimab: 200mg i.v. q3w.
Active Comparator: Regorafenib; Regorafenib alone.	Drug: Regorafenib; 160 mg p.o. qd for 3 weeks of every 4 week cycle.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression free survival (PFS) assessed by investigators according to Response Evalutaion Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST)	The time from date of randomization until the first occurrence of disease progression or death due to any cause, whichever occurs first.	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events (AEs)	Number of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), AE of special interest (AESI), serious adverse event (SAE), assessed by NCI CTCAE v5.0.	24 months
Overall survival (OS)	The time from date of randomization to death due to any cause.	24 months
Time to Progression (TTP) assessed by investigators according to RECIST 1.1 and irRECIST	The time from date of randomization until the first occurrence of disease progression.	24 months
Objective response rate (ORR) assessed by investigators according to RECIST 1.1 and irRECIST.	The percentage of patients who had a best overall tumor response rating of complete response (CR) or partial response (PR).	24 months
Disease control rate (DCR) assessed by investigators according to RECIST 1.1 and irRECIST	The percentage of patients who had a tumor response rating of CR, PR, or stable disease (SD).	24 months
PFS assessed by investigators according to Modified RECIST (mRECIST)	The time from date of randomization until the first occurrence of disease progression or death due to any cause, whichever occurs first.	24 months
TTP assessed by investigators according to mRECIST.	The time from date of randomization until the first occurrence of disease progression.	24 months
ORR assessed by investigators according to mRECIST	The percentage of patients who had a best overall tumor response rating of CR or PR.	24 months
DCR assessed by investigators according to mRECIST.	The percentage of patients who had a tumor response rating of CR, PR, or SD.	24 months

Collaborators and Investigators

• Sponsor: Second Affiliated Hospital of Guangzhou Medical University
• Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen People's Hospital; Third Affiliated Hospital, Sun Yat-Sen University; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University; Peking University Shenzhen Hospital; Shantou Central Hospital; Second Affiliated Hospital of Nanchang University; Cancer Hospital of Guangxi Medical University; Yuebei People's Hospital; ZhuHai Hospital; The First People's Hospital of Zhaoqing; Jiangmen Central Hospital; Jieyang People's Hospital; Zhaoqing Gaoyao People's Hospital
• Investigators: Study Chair: Kangshun Zhu, Dr., Second Affiliated Hospital of Guangzhou Medical University

Study record dates

Study Major Dates

• Study Start (Actual): January 9, 2021
• Primary Completion (Anticipated): July 8, 2023
• Study Completion (Anticipated): December 31, 2023

Study Registration Dates

• First Submitted: January 20, 2021
• First Submitted That Met QC Criteria: January 20, 2021
• First Posted (Actual): January 22, 2021

Study Record Updates

• Last Update Posted (Actual): November 10, 2022
• Last Update Submitted That Met QC Criteria: November 8, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Keywords: Regorafenib; Hepatocellular carcinoma; Sintilimab; Second-line treatment
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Liver Diseases; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular
• Other Study ID Numbers: MIIR-05

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No